These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 23254964)

  • 1. Hypertension as a predictive biomarker in bevacizumab treatment for colorectal cancer patients.
    Tahover E; Uziely B; Salah A; Temper M; Peretz T; Hubert A
    Med Oncol; 2013 Mar; 30(1):327. PubMed ID: 23254964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature.
    Lombardi P; Rossini D; Crespi V; Germani MM; Bergamo F; Pietrantonio F; Santini D; Allegrini G; Daniel F; Pagani F; Antoniotti C; Zaniboni A; Conca V; Latiano TP; Boccaccino A; Passardi A; Tamburini E; Masi G; Di Maio M; Cremolini C
    Cancer Treat Rev; 2022 Feb; 103():102326. PubMed ID: 35016085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy.
    Österlund P; Soveri LM; Isoniemi H; Poussa T; Alanko T; Bono P
    Br J Cancer; 2011 Feb; 104(4):599-604. PubMed ID: 21304526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of hypertension as a marker of bevacizumab efficacy.
    Ryanne Wu R; Lindenberg PA; Slack R; Noone AM; Marshall JL; He AR
    J Gastrointest Cancer; 2009; 40(3-4):101-8. PubMed ID: 19921473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of hypertension and proteinuria as markers of efficacy in antiangiogenic therapy for metastatic colorectal cancer.
    Khoja L; Kumaran G; Zee YK; Murukesh N; Swindell R; Saunders MP; Clamp AR; Valle JW; Wilson G; Jayson GC; Hasan J
    J Clin Gastroenterol; 2014; 48(5):430-4. PubMed ID: 24153157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer.
    Boisen MK; Johansen JS; Dehlendorff C; Larsen JS; Østerlind K; Hansen J; Nielsen SE; Pfeiffer P; Tarpgaard LS; Holländer NH; Keldsen N; Hansen TF; Jensen BB; Jensen BV
    Ann Oncol; 2013 Oct; 24(10):2554-2559. PubMed ID: 23864097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: a single-center experience and a critical review of the literature.
    Lombardi G; Zustovich F; Farina P; Fiduccia P; Della Puppa A; Polo V; Bertorelle R; Gardiman MP; Banzato A; Ciccarino P; Denaro L; Zagonel V
    Anticancer Drugs; 2013 Jan; 24(1):90-7. PubMed ID: 23075631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab.
    Scartozzi M; Galizia E; Chiorrini S; Giampieri R; Berardi R; Pierantoni C; Cascinu S
    Ann Oncol; 2009 Feb; 20(2):227-30. PubMed ID: 18842611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer: A Pooled Analysis of 4 Prospective Trials of Gemcitabine-based Therapy With Bevacizumab.
    Pant S; Martin LK; Geyer S; Wei L; Van Loon K; Sommovilla N; Zalupski M; Iyer R; Fogelman D; Ko AH; Bekaii-Saab T
    Am J Clin Oncol; 2016 Dec; 39(6):614-618. PubMed ID: 25068471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
    Tappenden P; Jones R; Paisley S; Carroll C
    Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
    Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
    J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab.
    Zhong J; Ali AN; Voloschin AD; Liu Y; Curran WJ; Crocker IR; Shu HK
    Cancer; 2015 May; 121(9):1456-62. PubMed ID: 25557543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.
    Kozloff M; Yood MU; Berlin J; Flynn PJ; Kabbinavar FF; Purdie DM; Ashby MA; Dong W; Sugrue MM; Grothey A;
    Oncologist; 2009 Sep; 14(9):862-70. PubMed ID: 19726453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin(®) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study.
    Hurwitz HI; Bekaii-Saab TS; Bendell JC; Cohn AL; Kozloff M; Roach N; Mun Y; Fish S; Flick ED; Grothey A;
    Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):323-32. PubMed ID: 24686090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C
    JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of high dose d,l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab.
    Budai B; Nagy T; Láng I; Hitre E
    Angiogenesis; 2013 Jan; 16(1):113-21. PubMed ID: 22956187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients.
    De Stefano A; Carlomagno C; Pepe S; Bianco R; De Placido S
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1207-13. PubMed ID: 21409384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative.
    Betge J; Barat A; Murphy V; Hielscher T; Van Grieken NC; Belle S; Zhan T; Härtel N; Kripp M; Bacon O; Cordes M; Kay EW; Verheul HM; Neerincx M; Hennessy B; Hofheinz RD; Gaiser T; Ylstra B; Prehn JH; Lambrechts D; Byrne AT; Ebert MP; Schulte N
    Digestion; 2016; 94(3):129-137. PubMed ID: 27756074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.
    Sogabe S; Komatsu Y; Yuki S; Kusumi T; Hatanaka K; Nakamura M; Kato T; Miyagishima T; Hosokawa A; Iwanaga I; Sakata Y; Asaka M
    Jpn J Clin Oncol; 2011 Apr; 41(4):490-7. PubMed ID: 21303790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients.
    Scartozzi M; Giampieri R; Maccaroni E; Del Prete M; Faloppi L; Bianconi M; Galizia E; Loretelli C; Belvederesi L; Bittoni A; Cascinu S
    Br J Cancer; 2012 Feb; 106(5):799-804. PubMed ID: 22315053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.